Acorda Therapeutics (OTCPK:ACOR.Q) - Aandelenkoers, Nieuws & Analyse

ACOR.Q Overzicht aandelen

A biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. Meer informatie

ACOR.Q fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( $37K )

Heeft minder dan 1 jaar cash runway

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Negatief eigen vermogen

Acorda Therapeutics, Inc. Concurrenten

Athenex

OTCPK:ATNX.Q

US$131.7k

Peak Bio

OTCPK:PKBO

US$1.6m

Endonovo Therapeutics

OTCPK:ENDV

US$317.5k

International Stem Cell

OTCPK:ISCO

US$960.5k

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Acorda Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$0.02
52 Week Hoogtepunt	US$18.00
52 Week Laag	US$0.013
Bèta	1.69
11 maand verandering	-84.62%
3 maanden verandering	-96.88%
1 Jaar Verandering	-99.88%
33 jaar verandering	-99.97%
5 jaar verandering	-99.99%
Verandering sinds IPO	-100.00%

Recent nieuws en updates

Recent updates

Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?

Feb 21

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement

Dec 18

Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?

Jun 05

Acorda wins $16.5M in Ampyra arbitration case with Alkermes

Oct 17

Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on vote

Oct 10

CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action

Jun 17

Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

May 26

Acorda Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts

Mar 09

Rendement voor aandeelhouders

	ACOR.Q	US Biotechs	US Markt
7D	-28.5%	2.4%	2.2%
1Y	-99.9%	16.2%	31.7%

Rendement versus industrie: ACOR.Q presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 16.2 % opleverde.

Rendement versus markt: ACOR.Q presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.7 % opleverde.

Prijsvolatiliteit

Is ACOR.Q's price volatile compared to industry and market?
ACOR.Q volatility
ACOR.Q Average Weekly Movement	55.6%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van ACOR.Q is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van ACOR.Q is het afgelopen jaar gestegen van 34% naar 56%.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1995	102	Ron Cohen	www.acorda.com

Acorda Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Acorda Therapeutics zich tot de beurswaarde?
ACOR.Q fundamentele statistieken
Marktkapitalisatie	US$37.39k
Inkomsten(TTM)	-US$263.42m
Inkomsten(TTM)	US$115.66m

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is ACOR.Q overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ACOR.Q resultatenrekening (TTM)
Inkomsten	US$115.66m
Kosten van inkomsten	US$20.48m
Brutowinst	US$95.19m
Overige uitgaven	US$358.61m
Inkomsten	-US$263.42m

Laatst gerapporteerde inkomsten

Mar 31, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-212.08
Brutomarge	82.30%
Nettowinstmarge	-227.75%
Schuld/Eigen Vermogen Verhouding	-103.1%

Hoe presteerde ACOR.Q op de lange termijn?

Bekijk historische prestaties en vergelijking

ACOR.Q Overzicht aandelen

Risicoanalyse

Acorda Therapeutics, Inc. Concurrenten

OTCPK:ATNX.Q

US$131.7k

OTCPK:PKBO

US$1.6m

OTCPK:ENDV

US$317.5k

OTCPK:ISCO

US$960.5k

Prijsgeschiedenis en prestaties

Recent nieuws en updates

First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.

Acorda Therapeutics Files Form 15

Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.

Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024

Acorda Therapeutics Announces Delisting from Nasdaq

Recent updates

First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.

Acorda Therapeutics Files Form 15

Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.

Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024

Acorda Therapeutics Announces Delisting from Nasdaq

Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from NASDAQ Composite Index

Motion for Asset Sale Filed by Acorda Therapeutics, Inc.

Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million.

Acorda Therapeutics, Inc. Filed for Bankruptcy

Acorda Therapeutics, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?

New minor risk - Share price stability

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement

Third quarter 2023 earnings released: US$7.16 loss per share (vs US$11.41 loss in 3Q 2022)

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA

New minor risk - Shareholder dilution

Acorda Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$7.55 loss per share (vs US$55.63 loss in 2Q 2022)

Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Acorda Therapeutics Announces Completion of Reverse Stock Split to Enable the Company to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing on the Nasdaq Global Select Market

Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?

Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing

First quarter 2023 earnings released: US$0.69 loss per share (vs US$1.85 loss in 1Q 2022)

Acorda Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$3.35 loss per share (vs US$9.79 loss in FY 2021)

Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement

Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request A Hearing

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Acorda Therapeutics, Inc. Provides Earnings Guidance for the Years of 2022, 2023, 2024, 2025, 2026 and 2027

Acorda Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Acorda wins $16.5M in Ampyra arbitration case with Alkermes

Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on vote

Acorda inks license deal with Asieris for pre-clinical drug

Acorda Therapeutics Announces Resignation of Lauren Sabella as Chief Operating Officer

Acorda Therapeutics announces resignation of COO

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings released: US$2.78 loss per share (vs US$2.29 loss in 2Q 2021)

Acorda Therapeutics Receives Deficiency Letter Listing Qualifications Department of Nasdaq Stock Market

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Acorda Therapeutics, Inc. Announces Board Changes

Insufficient new directors

Third quarter 2021 earnings released: US$2.43 loss per share (vs US$0.92 profit in 3Q 2020)

Acorda Therapeutics: Managing The Transition

Independent Director Barry Greene has left the company

Independent Director Catherine D. Strader has left the company

Second quarter 2021 earnings released: US$2.29 loss per share (vs US$2.19 loss in 2Q 2020)

Acorda Therapeutics Continues To Maneuver For A Turnaround

CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action

Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

First quarter 2021 earnings released: US$3.53 loss per share (vs US$0.81 loss in 1Q 2020)

Acorda Therapeutics, Inc. Provides Financial Guidance for the Full Year of 2021

Acorda Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

Analysts increase revenue estimates to US$95.7m